Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.
Massari F, Modena A, Ciccarese C, Pilotto S, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. Massari F, et al. Among authors: porta c. Crit Rev Oncol Hematol. 2016 Feb;98:254-63. doi: 10.1016/j.critrevonc.2015.11.009. Epub 2015 Nov 17. Crit Rev Oncol Hematol. 2016. PMID: 26638863
Weekly taxanes in metastatic breast cancer (review).
Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S. Zimatore M, et al. Among authors: porta c. Oncol Rep. 2002 Sep-Oct;9(5):1047-52. Oncol Rep. 2002. PMID: 12168071 Review.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Motzer RJ, et al. Among authors: porta c. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22. Lancet. 2008. PMID: 18653228 Clinical Trial.
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Gore ME, et al. Among authors: porta c. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Santini D, et al. Among authors: porta c. J Cell Physiol. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. J Cell Physiol. 2011. PMID: 20857484
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G. Santini D, et al. Among authors: porta c. PLoS One. 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234. PLoS One. 2011. PMID: 21559440 Free PMC article.
955 results